A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia

[1]  H. Ljunggren,et al.  Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML , 2018, Clinical Cancer Research.

[2]  K. Rezvani,et al.  Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. , 2017, Blood.

[3]  T. Waldmann,et al.  A Phase I Study of Intravenous NCI IL-15 to Enhance Adoptively Transferred NK Cells Uncovers Defects in CD16 Triggered IFNγ Production and Competition Between Donor NK and Recipient T Cells , 2015 .

[4]  C. Pui,et al.  Natural killer cell therapy in children with relapsed leukemia , 2015, Pediatric blood & cancer.

[5]  M. Carroll,et al.  CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia , 2015, Leukemia.

[6]  S. Pittaluga,et al.  Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. , 2015, Blood.

[7]  S. Raimondi,et al.  Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Baccarani,et al.  Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. , 2011, Blood.

[9]  Elaine Coustan-Smith,et al.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. , 2010, The Lancet. Oncology.

[10]  C. Pui,et al.  NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Campana,et al.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. , 2009, Cancer research.

[12]  M. Martinetti,et al.  Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. , 2009, Blood.

[13]  D. Tough,et al.  In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection , 2007, Immunology.

[14]  M. Martelli,et al.  Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. , 2006, Blood.

[15]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[16]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[17]  M. Caligiuri,et al.  What does it take to make a natural killer? , 2003, Nature Reviews Immunology.

[18]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[19]  A. Criel,et al.  Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing , 2001, Bone Marrow Transplantation.

[20]  K. Nakachi,et al.  Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population , 2000, The Lancet.

[21]  J. Klein,et al.  IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE , 1997, British journal of haematology.

[22]  Dean Anthony Lee,et al.  Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL21. , 2016, Methods in molecular biology.

[23]  R. Kapp,et al.  Food, Drug, and Cosmetic Act , 2005 .

[24]  Peter Parham,et al.  KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. , 2002, Annual review of immunology.